5 Analysts Assess Century Therapeutics: What You Need To Know
Portfolio Pulse from Benzinga Insights
Over the past three months, five analysts have shared their insights on Century Therapeutics (NASDAQ:IPSC), with ratings ranging from bullish to bearish. The average 12-month price target is $13.6, with a high of $24.00 and a low of $9.00. Recent financial performance shows a decline in revenue growth and challenges in profitability, but the company has a strong ROE and ROA, and a prudent debt management strategy.

June 04, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Century Therapeutics (NASDAQ:IPSC) has received mixed analyst ratings over the past three months, with an average 12-month price target of $13.6. The company's recent financial performance shows a significant decline in revenue growth and challenges in profitability, but it has strong ROE and ROA, and a prudent debt management strategy.
The mixed analyst ratings and the average price target of $13.6 suggest a neutral short-term impact on the stock price. The company's financial performance shows both strengths (ROE, ROA, debt management) and weaknesses (revenue decline, profitability challenges), leading to a balanced outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100